{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T23:09:26Z","timestamp":1761952166574,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1053\/j.seminhematol.2008.07.003","type":"journal-article","created":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T04:25:13Z","timestamp":1219983913000},"page":"S2-S6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"S2","title":["Treatment of Follicular Non-Hodgkin's Lymphoma: The Old and the New"],"prefix":"10.1053","volume":"45","author":[{"given":"Jonathan W.","family":"Friedberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2008.07.003_bib1","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib2","doi-asserted-by":"crossref","first-page":"892a","DOI":"10.1182\/blood.V104.11.3268.3268","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) Is superior to WHO\/REAL histological grade for identifying high-risk patients: A retrospective review of the MSKCC experience in 260 patients with follicular lymphoma","volume":"104","author":"Halaas","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib6","doi-asserted-by":"crossref","first-page":"293a","DOI":"10.1182\/blood.V106.11.1000.1000","article-title":"Prospective validation of the FLIPI: Baseline distribution and correlates in newly diagnosed follicular lymphoma (FL) patients from the US: First report of the National Lympho-Care Study","volume":"106","author":"Link","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib7","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib8","doi-asserted-by":"crossref","first-page":"50a","DOI":"10.1182\/blood.V104.11.161.161","volume":"104","author":"Hiddemann","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib9","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/jco.2006.24.18_suppl.7508","article-title":"Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts)","volume":"24","author":"Foussard","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib11","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V108.11.481.481","article-title":"MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkins lymphoma (NHL)","volume":"108","author":"Marcus","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib12","doi-asserted-by":"crossref","first-page":"147a","DOI":"10.1182\/blood.V108.11.484.484","article-title":"Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma\u20144 year follow-up results of a phase III trial of East German Study Group Hematology and Oncology (OSHO#39)","volume":"108","author":"Herold","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib13","first-page":"428s","article-title":"Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS)","volume":"24","author":"Friedberg","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014A randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib18","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib19","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib20","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib22","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2007-04-084996","article-title":"Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products","volume":"110","author":"Ahn","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib24","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","article-title":"A novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma","volume":"26","author":"Chauhan","year":"2007","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3816\/CLM.2005.n.046","article-title":"Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma","volume":"6","author":"O'Connor","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ijc.21805","article-title":"Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma","volume":"119","author":"Leonard","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib28","doi-asserted-by":"crossref","first-page":"441s","DOI":"10.1200\/jco.2007.25.18_suppl.8003","article-title":"Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses","volume":"25","author":"Stewart","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib29","doi-asserted-by":"crossref","first-page":"208a","DOI":"10.1182\/blood.V108.11.694.694","article-title":"Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results","volume":"108","author":"De Vos","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib31","doi-asserted-by":"crossref","first-page":"457s","DOI":"10.1200\/jco.2007.25.18_suppl.8066","article-title":"Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed\/refractory indolent non-Hodgkin","volume":"25","author":"Witzig","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib32","first-page":"178","article-title":"Targeting apoptosis pathways in cancer therapy","volume":"55","author":"Ghobrial","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib33","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.3816\/CLM.2006.s.005","article-title":"New directions in the treatment of mantle cell lymphoma: An overview","volume":"1","author":"Goy","year":"2006","journal-title":"Clin Lymphoma Myeloma 7 Suppl"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2004.05239.x","article-title":"Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab","volume":"127","author":"Ramanarayanan","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.cco.0000142074.67968.eb","article-title":"Bcl-2 antisense therapy in hematologic malignancies","volume":"16","author":"Chanan-Khan","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2004.11.002","article-title":"Bcl-2 antisense therapy in B-cell malignancies","volume":"19","author":"Chanan-Khan","year":"2005","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib37","doi-asserted-by":"crossref","first-page":"757a","DOI":"10.1182\/blood.V110.11.2569.2569","article-title":"A phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed\/refractory mantle cell lymphoma","volume":"110","author":"Goy","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib38","doi-asserted-by":"crossref","first-page":"412a","DOI":"10.1182\/blood.V110.11.1371.1371","article-title":"A phase 1\/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies","volume":"110","author":"Wilson","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.07.003_bib39","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4161\/cbt.4.12.2315","article-title":"How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy","volume":"4","author":"Blagosklonny","year":"2005","journal-title":"Cancer Biol Ther"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196308001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196308001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:19:11Z","timestamp":1758521951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196308001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":35,"alternative-id":["S0037196308001194"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.07.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Follicular Non-Hodgkin's Lymphoma: The Old and the New","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}